Apoptosis is a morphologically distinct form of cell death involved in many physiological and pathological processes. The death receptor CD95 (APO-1/Fas) and its ligand (L) CD95L are critically involved in activation-induced-cell-death (AICD) of activated T-cells. Here we show that the anti-inflammatory sesquiterpene lactone parthenolide derived from the European traditional herb-medicine feverfew and many Mexican India medicinal plants suppresses expression of the CD95L and CD95 at the mRNA levels, thus, preventing T-cells from AICD. We demonstrate that parthenolide blocks NF-kB binding to the two NF-k binding sites of the CD95L promoter and suppresses promoter activity upon T-cell activation. Aberrant expression of CD95 and, particularly CD95L is dangerous and may lead to severe diseases. Our study indicates that parthenolide supports T-cell survival by downregulating the CD95 system, at least in part, and, therefore, may have therapeutic potential as a new anti-apoptotic substance against AICD in T-cells.
Introduction
Apoptosis is the most common form of eukaryotic cell death and is a process required for the normal development of an organism. CD95L, a type II trans-membrane protein of the tumor necrosis factor (TNF) family, is an important molecule implicated in activation-induced apoptosis of T-lymphocytes, the maintenance of immunologically privileged anatomical sites, and CTL and NK cell-mediated cytotoxicity against a variety of tumor and virus-infected cells.
1,2 CD95 mediated apoptosis is also known to be a mechanism for maintenance of peripheral tolerance and for termination of an ongoing immune response. 2, 3 However, aberrant expression of CD95L and CD95 is dangerous and leads to severe diseases which have been well documented in the pathogenesis of lymphadenopathy and autoimmunity in human and in animal models. 4 ± 9 Increased expression of CD95L is also shown to be responsible, at least in part, for the progressive loss of CD4 + T-cells in HIV-1-infected individuals. 10 Expression of CD95L is restricted to a few cell types such as activated T-cells, macrophages, and to cells in tissues of immune privileged sites such as the testis and the eye. CD95L is not present in resting T-cells and is highly expressed upon T-cell activation through the TCR. 11 In addition, a variety of environmental stress stimuli such as UV irradiation, g-irradiation and DNA-damaging agents, can induce CD95L expression. 12, 13 In contrast, CD95 is expressed on various tissues. On peripheral blood T-cells, CD95 expression is low and only increased after T-cell activation.
14 Binding of CD95L to CD95 results in rapid apoptosis of CD95 bearing cells. Since CD95L expression is a crucial step leading to CD95-mediated apoptosis, many studies have been performed to explore the molecular mechanisms involved in CD95L activation and to identify potential therapeutic targets. Transcription factors such as NF-AT, Egr-1, 2, 3, NF-kB, AP-1 and SP-1 have been shown to participate in regulation of CD95L expression in T-cells (for a review see 15 ). Some of the transcription factors such as NF-AT and Egr, have been shown to play an important role in CD95L expression. Targeting NF-AT activity using the immunosuppressive drug Cyclosporin A (CsA) can block CD95L mRNA expression and, consequently, block activation-induced-cell-death (AICD) in Tcells. 16 Recently, Sesquiterpene lactones (SLs), derived from Mexican India medicinal plants and European feverfew, have raised considerable interest because of their antiinflammatory and complex pharmacological action. 17, 18 SLs containing herbs are frequently used by Mexican Indians for treatment of stomach-ache, infection of the skin and other organs. 17, 18 Feverfew has been used in traditional medicine in the prophylactic treatment of migraine. 19 lead to phosphorylation, ubiquitinylation, and the subsequent degradation of IkB proteins. The DNA-binding subunits of NF-kB immigrate into the nucleus and activate expression of numerous target genes that are important for inflammatory responses and the immune response (for review see 23 ). SLs were shown to specifically inhibit NF-kB by targeting the IkB kinase complex (IKKa and IKKb) and preventing phosphorylation of IkB. 20, 21 More recently, it was also shown that SLs may directly inhibit NF-kB by alkylating p65 at Cysteine 38 which is required for DNA binding. 22 We have previously identified two NF-kB regulatory sites in the human CD95L promoter and shown that these two sites are involved in transactivation of the CD95L promoter upon T-cell activation. 24 We and others have previously shown that the HIV-1 Tat protein essential for efficient HIV-1 gene expression and replication enhances apoptosis via up-regulation of CD95L expression. 25, 26 The two NF-kB binding sites of the CD95L promoter may, at least in part, respond to HIV-1 Tat. 24 In addition, the CD95 promoter and CD95 mRNA were also shown to be up-regulated by NF-kB after stimulation of T-cells by PMA and ionomycin. 27 Therefore, NF-kB may play an important role in regulation of AICD in T-cells. In this study, we asked whether CD95-mediated AICD in T-cells can be prevented via targeting NF-kB function by SLs. We show here a dose-dependent down-regulation of AICD in T-cells by the anti-inflammatory SL parthenolide. CD95L expression is significantly inhibited by parthenolide at the mRNA and protein levels. Inhibition of CD95 mRNA and protein expression was also observed. Our studies indicate that parthenolide is a potent inhibitor of CD95L gene expression and might be used for development of drugs in prevention of CD95L-mediated apoptosis.
Results

Parthenolide protects apoptosis in activated Jurkat T-cells
Jurkat T-cells express both CD95 and CD95L and have been used as a model system for apoptosis studies. 16 To analyze the effect of parthenolide on T-cell death, a Jurkat T-cell subclone J-27 susceptible to TCR-induced AICD was used for this study. We found that parthenolide significantly downregulated AICD in these cells. A representative result is shown in Figure 1 . Activation of J-27 T-cells through TCR by aCD3 antibody resulted in AICD. In the presence of parthenolide, aCD3-induced cell death was down-regulated in a dose-dependent manner (Figure 1) . Approximate 50 ± 60% reduction in apoptotic cells was seen in the presence of 2.0 ± 3.0 mM parthenolide (Figure 1) . To analyze the toxicity of parthenolide, J-27 cells were cultured with different doses of parthenolide for different time points and the live cells were counted by Trypan blue dye exclusion. No toxicity was seen when the cells were cultured with up to 2.5 mM parthenolide for 24 h (Figure 2A ) or longer (data not shown). Slight inhibition of cell proliferation was seen by 5 mM parthenolide. Ten mM parthenolide completely blocked cell proliferation and also led to an increase in dead cells (Figure 2A ). Correlatively, AICD was largely inhibited by up to 5 mM of parthenolide ( Figure 2B ). Ten mM parthenolide appeared to be toxic and had no inhibitory effect on AICD ( Figure 2B ). In the presence of the CD95 blocker soluble CD95-Fc or the CD95L blocking antibody NOK1, AICD was largely inhibited demonstrating that CD95 and CD95L represent the main death system involved in AICD in J-27 T-cells ( Figure 2C ).
Parthenolide inhibits CD95L and CD95 mRNA expression in activated Jurkat T-cells Since the CD95 system plays an important role in AICD in Tcells, we next investigated wether parthenolide affects expression of CD95 and CD95L. J-27 cells were stimulated by either PMA/ionomycin or aCD3/aCD28 in the presence or absence of 5 mM parthenolide for different times and total RNA was isolated for RT ± PCR analysis. Upon T-cell activation, CD95L mRNA in J-27 cells was rapidly induced and its expression was substantially reduced in the presence of parthenolide ( Figure 3A,B) . Quantitative analysis by realtime RT ± PCR showed an approximate 50% reduction in CD95L mRNA expression by treatment with 5 mM parthenolide ( Figure 3C ). In contrast, the levels of CD95 mRNA were only slightly increased upon activation of the J-27 cells and were only marginally (15 ± 20%) affected by parthenolide ( Figure 3A ± C).
Parthenolide suppresses CD95L and CD95 promoter activity
To further investigate whether down-regulation of CD95L and CD95 mRNA expression by parthenolide occurred at the transcriptional level, we examined the effect of parthenolide on CD95L and CD95 promoter activity. Luciferase reporter constructs containing up to 7860 of the human CD95L and up to 71740 of the human CD95 promoters were used for transient transfection studies. Different doses of parthenolide were added to the cell culture 1 h before T-cell activation. Activation of J-27 cells with aCD3 or with PMA/ionomycin led to an approximate sevenfold increase in CD95L promoter activity. Administration of parthenolide significantly (70 ± 100%) reduced PMA/ionomycin-or aCD3-induced CD95L promoter activity ( Figure 4A ). The activity of the CD95 promoter was only slightly increased upon T-cell activation ( Figure 4B ). Nevertheless, the increased promoter activity was also inhibited by parthenolide by approximate 40 ± 60% ( Figure 4B ). In contrast, the Bax promoter whose activity is not positively regulated by NF-kB, 28 was not down-regulated by parthenolide ( Figure 4C ). Thus, parthenolide reduces CD95L and CD95 expression at the transcriptional level and, consequently, attenuates AICD in J-27 cells.
Parthenolide inhibits NF-kB binding to the CD95L promoter NF-kB binding sites
Since a pronounced reduction of the CD95L promoter was seen in the presence of parthenolide in transfection studies, we further focused on the molecular mechanisms by which parthenolide down-regulates CD95L transcription. The human CD95L promoter contains two NF-kB binding sites at the 530 and 50 24 and three Egr/NF-AT composite sites at the 7120, 7180 and 7680 regions. 29 Since these sites have been shown to be important for activation-dependent promoter activity, 24,29 ± 33 an electrophoretic mobility shift assay (EMSA) was performed to analyze the effect of parthenolide on DNA-binding of transcription factors to these regulatory elements. Oligonucleotides containing the NF-kB site at the 7530 and 750 and the Egr and NF-AT site at the 7120 and 7180 regions were used as probes and incubated with nuclear extracts isolated from J-27 cells activated in the presence or absence of parthenolide. Parthenolide has been shown to be a potent inhibitor of NF-kB. Thus, it blocked binding of inducible nuclear factors to the two NF-kB elements ( Figure 5A ,B). In contrast, the inducible complexes formed on the Egr-and NF-AT-binding sites (at 7120 and 7 180 regions) were not influenced by parthenolide ( Figure 5A ,B).
As controls, the constitutive DNA-binding factor NF-Y was used for equal loading of proteins ( Figure 5A ,B). Antibody analysis demonstrated that the complexes inhibited by parthenolide contain the NF-kB family of proteins, p50 and p65: the complex formed on 750 and 7530 were partially inhibited by ap50 and ap65 antibodies ( Figure 6C ). The specificity of the ap65 antibody has been controlled by its capability to supershift ectopically expressed p65 protein binding on a typical NF-kB binding site and did not supershift other transcription factors such as SP1 (data not shown).
Recently, it was shown that SLs may directly inhibit NFkB DNA binding by alkylating p65 at Cys38. 22 Therefore, we further investigated such direct effect of parthenolide on NF-kB DNA binding activity in EMSA. Nuclear extracts from PMA stimulated Jurkat cells (which contain the activated nuclear form of NF-kB) were pre-incubated with various concentrations of parthenolide or with the solvent as control and then analyzed for DNA binding activity of NF-kB in an EMSA. Increasing concentrations of parthenolide did not shown a significant effect on DNA binding of activated NFkB in vitro ( Figure 5D ). This result is in agreement with the previous study. 20 A slight reduction of NF-kB binding activity was seen when 50 mM parthenolide was used ( Figure 5D ). However, in the presence of 50 mM of parthenolide, more than 80% cells die in several hours via necrosis (data not shown). Thus, inhibition of NF-kB binding to its target site by parthenolide observed in our study is most likely regulated by blockage of NF-kB nuclear translocation.
To confirm that NF-kB is involved in regulation of transcriptional activity of the two elements, we cotransfected the luciferase reporter constructs containing multiple copies of either one of the CD95L NF-kB sites with expression vectors encoding the NF-kB inhibitory proteins IkBa and IkBb 34 into J-27 cells. Ectopic expression of IkBa or IkBb down-regulated activities of both elements ( Figure  6A ). As a control, the Bax promoter was not suppressed by IkBa and IkBb in J-27 cells ( Figure 6A ). A dose-dependent suppression of the CD95L NF-kB-mediated transcriptional activity was also observed ( Figure 6B ). It was shown that parthenolide did not affect activation of the MAP kinases JNK and p38 21 and did not influence DNA-binding of the inducible transcription factor AP-1. 35 Along this line, the transcriptional activity driven by three copies of a typical AP-1 element was not affected by parthenolide ( Figure 6A ). Thus, parthenolide can block NF-kB binding to the CD95L NF-kB sites and attenuate transcriptional activity.
Parthenolide protects apoptosis in restimulated human peripheral blood T-cells
To further analyze the protection effect of parthenolide on Tcell death, freshly isolated human peripheral blood T-cells were prestimulated for 6 days (referred to as day 6 T-cells) 14 and subsequently restimulated via the TCR by plate-bound aCD3 antibodies. Analysis of CD95 and CD95L mRNA expression levels of restimulated day 6 T-cells showed that both CD95 and CD95L mRNA expression were dosedependently down-regulated by parthenolide ( Figure 7A) . Evaluation of the CD95 and CD95L mRNA expression levels by real-time quantitative PCR showed a 50 ± 75% reduction of CD95L mRNA expression at the 4 h activation time point in the presence of 1.25 ± 5.0 mM parthenolide ( Figure 7B ). Significant down-regulation of CD95 mRNA expression (23 ± 50%) by parthenolide was also observed ( Figure 7B ).
To further investigate the effect of parthenolide on CD95L and CD95 expression, we analyzed protein expression levels of CD95L and CD95 produced by activated T-cells. Since surface expression of human CD95L is regulated by metalloproteinases, day 6 T-cells were activated via aCD3 stimulation in the presence of metalloprotease inhibitors to increase expression of the membrane-bound ligand. As shown in Figure 8A , in correspondence to the reduction of CD95L mRNA levels, parthenolide inhibited aCD3-induced increase in CD95L protein expression levels. Restimulation of day 6 T-cells in the presence of parthenolide also resulted in approximately 50% reduction of CD95 expression ( Figure 8B ). Primary resting human peripheral blood T-cells are resistant to activation induced apoptosis.
14 Restimulation of day 6 Tcells, however, results in AICD. Similar to the results obtained with J-27 cells, parthenolide suppressed AICD in restimulated peripheral blood T-cells in a dose-dependent fashion ( Figure 8C) . A 30±55% reduction in apoptotic cells can be shown in the presence of 12.5 ± 5.0 mM parthenolide in the culture medium ( Figure 8C) . Thus, the antiinflammatory SL parthenolide has an inhibitory effect on CD95-mediated AICD in activated T-cells.
Discussion
Parthenolide-containing herbs have been traditionally used for treatment of inflammations. The anti-inflammatory activities of these herbs are partially due to their anti-NF-kB effects. NF-kB is involved in transcriptional activation of CD95L gene expression in activated T-cells. In this study, we show that parthenolide suppresses the CD95L promoter activity by down-regulation of transcriptional activity of NF-kB and, consequently, down-regulates CD95L mRNA and protein expression and CD95-mediated AICD. High dose of parthenolide is toxic as shown in our study that 10 mM of parthenolide completely inhibited T-cell proliferation and resulted in an increase in dead cells. Twenty mM parthenolide kill 80 ± 90% cells in 24 h (data not shown). At a higher dose (510 mM) of parthenolide, cells die via necrosis because no increase of DNA fragmentation could be detected when cells were treated with parthenolide alone (data not shown).
CD95 mRNA is constitutively expressed in Jurkat T-cells and is highly expressed in pre-activated peripheral blood Tcells. Nevertheless, real-time quantitative RT ± PCR revealed that CD95 mRNA expression is further upregulated upon activation of Jurkat T-cells or after restimulation of preactivated day 6 T-cells. NF-kB regulatory elements have been found in the CD95 promoter. 27, 36 When binding of NFkB was inhibited by the blockade of kB translocation or mutagenesis of the kB site, activation-dependent CD95 upregulation in Jurkat T-cells was lost. 27 In the presence of parthenolide, approximately 15 ± 20% down-regulation of CD95 mRNA levels were seen in Jurkat. The effect of parthenolide on CD95 expression of human peripheral blood T-cells is more significant: approximately 50% reduction of both CD95 mRNA and CD95 cell surface expression in restimulated day 6 T-cells was observed. Thus, parthenolide-mediated down-regulation of AICD may also involve CD95, although to a lesser extent than CD95L.
NF-kB transcription factors are key regulators of immune, inflammatory and acute phase responses and have been implicated in the control of cell proliferation and apoptotic signaling. A vast array of stimuli including TCR stimulation, certain environmental stressors, chemicals, ionizing and UV irradiation, chemotherapeutic agents, proto-oncogenes, and oxidative stress can induce NF-kB activities. 37, 38 However, the role of NF-kB in apoptosis . Whether NF-kB promotes or inhibits apoptosis appears to depend on the specific cell type and the type of inducer. SLs are potent inhibitors of NF-kB.
20±22
Thus, our study provides clear evidence showing that the pro-inflammatory transcription factor NF-kB exerts a proapoptotic role in AICD in T-cells.
Investigation of the molecular basis by which parthenolide inhibits NF-kB activity has revealed two mechanisms: direct inhibition of DNA binding by alkylating p65 at cysteine 38 22 and a second mechanism targeting the IkB kinase. 20, 21 Parthenolide possesses two reactive centers in form of an exomethylene group and an epoxide ring required to irreversibly inactivate its target molecules. 20 Garcia-Pineres et al. 22 demonstrated that the major effect of parthenolide on NF-kB DNA binding activity occurs via alkylation of p65 at cystein 38 and only a partial inhibition of IkB degradation was seen in Jurkat T-cells. An opposite observation was reported by Hehner et al. 20 showing that inhibition of NF-kB binding to its target site by parthenolide is due to prevention of IkB degradation and parthenolide itself does not interfere with DNA binding activity of activated NF-kB. 20 We have also investigated whether parthenolide exerts a direct inhibitory effect on DNA binding activity by adding different doses of parthenolide to the nuclear extracts. In agreement with the report of Hehner et al., 20 we did not observe a significant inhibitory effect of parthenolide on DNA binding activity of activated NF-kB. Garcia-Pineres et al. 22 performed their experiments with 20 mM of parthenolide which can be quite toxic to the Tcells. However, we do not exclude the possibility that parthenolide does, in part, exert a direct inhibitory effect on NF-kB DNA binding activity via alkylation.
SL parthenolide was shown to prevent the MAP3 kinase NIK and MEKK1 (identified as an interactor and activator of The mean values and S.D. are representative for three independent transfections. A luciferase reporter construct containing three copies of the AP-1 consensusbinding site was used as specificity control of the effect of parthenolide. Results represent the average of three to five independent transfection experiments both IKKa and IKKb) induced activation of both IKKs, but does not affect activation of p38 and c-Jun N-terminal kinase. 21 Parthenolide also does not interfere with activity of the Src family protein tyrosine kinases p59 fyn and p60
src . 20 The specificity of parthenolide has been also documented by other investigators showing that it does not influence the activity of other transcription factors such as AP-1, RBP-Jk, and Oct-1. 21, 35 Since parthenolide displays a relatively high degree of specificity for NF-kB, it may be justified in the future to develop parthenolides as new antiapoptotic drugs against AICD in T-cells.
Materials and Methods
Cell line and cell culture
The Jurkat T-leukemia cell clone J-27 was cultured in RPMI 1640 medium (GIBCO laboratories, Grand Island, NY, USA) supplemented with 10% FCS, 50 mg/ml gentamicin (GIBCO), 6 mM HEPES (GIBCO, 1 M solution), and 2 mM L-glutamine (GIBCO, 200 mM solution) at 378C and 5% CO 2 . Primary human T-cells were cultured in the presence of IL-2 as described previously.
14 Antibodies aAPO-1 antibody has been made in our laboratory. 40 The goat anti-mouse-PE was purchased from Jackson Immuno Research Laboratory Inc. The ap50 antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The aNF-kB/p65 was purchased from BIOMOL Research Laboratories, Inc. (Butler Pike, PA, USA). PE-labeled IgG antibody Streptavidin-PE, NOK-1 and Biotin-labeled NOK-1 antibodies were purchased for BDPharmingen (San Diego, CA, USA). The hybridoma secreting aCD28 was kindly provided by G Moldenhauer (DKFZ, Heidelberg, Germany).
Puri®cation of primary human T-lymphocytes
PBMC were collected from healthy adult donors. The mononuclear cells were isolated over Ficoll-Hypaque (Biochrom, Berlin, Germany), washed three times with PBS, and incubated at DMEM for 1 h in plastic tissue culture dishes at 378C in a 5% CO 2 incubator. Non-adherent lymphocytes cells were collected from the plastic dishes. T-cells were purified from the mixed lymphocyte population up to 90% purity using TB-Sep nylon wool columns (Cell-Tech GmbH, Bad-Du È rkheim, Germany) according to the manufacturer's instruction.
AICD
Freshly isolated blood T-cells were stimulated by PHA and cultured in the presence of IL-2 for 6 days as described.
14 The day 6 T-cells were then treated without or with different doses of parthenolide (Sigma, St. Louis, MO, USA) for 1 h and subsequently cultured in 96-well-flat-bottomed plates coated with a-CD3 (OKT3, 50 mg/ml). Cell death was assessed by propidium iodide (PI) uptake and analyzed by FACS. 14 J-27 T leukemia cells were induced either with PMA (10 ng/ml) (Sigma, St. Louis, MO, USA) and ionomycin (0.5 mM) (Calbiochem, Bad Soden, Germany) or with plate-bound a-CD3 (OKT3, 50 mg/ml) for 24 h in the presence of parthenolide or equal amounts of the solvent ethanol. For controls, J-27 cells were stimulated in the absence or presence of CD95-Fc (50 mg/ml) 16 or NOK1 (50 mg/ml) for 24 h. Apoptotic nuclei were measured by propidium iodide (PI) uptake. 14 
Analysis of surface CD95L and CD95R protein expression
For CD95L analysis, day 6 T-cells were activated by plate-coated aCD3 (OKT3, 40 mg/ml) in the presence of matrix metalloproteinase inhibitors specific for CD95L (MMP inhibitor II, 4 mg/ml, Calbiochem, La Jolla, CA, USA). After indicated times, cells were collected by centrifugation, washed once with PBS. 5610 5 cells were resuspended in 100 ml PBS containing 5% FCS. The cells were incubated with Biotin-labeled aCD95L antibody (NOK-1, 0.05 mg/ml) at 48C for 15 min. Bound antibodies were detected by adding 100 ml PBS containing 0.025 mg/ml Streptavidin-PE and incubated at 48C for a further 15 min. Cells were washed once with PBS and resuspended in 200 ml PBS and subjected to FACS (FL2 Histogram) analysis. For CD95 analysis, day 6 T-cells were activated by aCD3 in the presence and absence of parthenolide as above. After 16 h activation, the cells (2610 5 ) were collected and suspended in 50 ml PBS containing 1 mg/ ml of aAPO-1 antibody and incubated at 48C for 15 min. Fifty ml of PBS containing 1 : 200 diluted goat a-mouse-PE were added to the cells and incubated at 48C for a further 15 min. Cells were washed once with PBS and resuspended in 100 ml PBS and subjected to FACS analysis. 
RNA preparation
J-27 cells and the peripheral blood T-cells were pre-cultured with different doses of parthenolide or a equal amounts of solvent ethanol for 1 h and then stimulated for indicated times with plate-bound a-CD3 antibodies or with PMA (10 ng/ml) (Sigma, St Louis, MO, USA) and ionomycin (0.5 mM) (CalBiochem, La Jolla, CA, USA). RNA was isolated using the RNeasy kit (Qiagen GmbH, Hilden, Germany) according to the manufacture s instructions.
Normal RT ± PCR
One mg of total RNA was reverse transcribed using the RT ± PCR kit (Perkin Elmer, Foster City, CA, USA). Aliquots were amplified in a DNA thermocycler (Startagene, Heidelberg, Germany) with 2.5 U recombinant Taq polymerase (Sigma, St Louis, MO, USA). Amplification products were separated by electrophoresis on 1.2% agarose gels. 
Real-time quantitative PCR
Real-time quantitative PCR has been previously described in detail. 41 The primers and fluorescent-labeled probes used in these studies are CD95L primers: forward 5'-AAAGTGGCCCATTTAACAGGC-3', reverse 5'-AAAGCAGGACAATTCCATAGGTG-3', probe 5'-TCCAACTCAAGGTCCATGCCTCTGG-3'; CD95 primers: forward 5'-ACTGTGACCCTTGCACCAAAT-3', reverse 5'-GCCACCCCAAGTTA-GATCTGG-3', probe 5'-AATCATCAAGGAATGCACACTCACCAGCA-3'; b-actin primers: forward 5'-ACCCACACTGTGCCCATCTACGA-3', reverse 5'-CAGCGGAACCGCTCATTGCCAATGG-3', probe 5'-ATGCCCTCCCCCATGCCATCCTGCGT-3'.
PCR was performed in a 12.5 ml reaction mixture (PCR kit from Eurogentech, Belgium) that contained 0.08 mg of reverse transcribed cDNA, 1.25 ± 7.5 pM forward primers, 22.5 pM reverse primers and 5 pM probe. For each sample three PCR were performed. The resulting relative increase in reporter fluorescent dye emission was monitored by the TagMan-system (GeneAmp 5700 sequence detection system and software, Perkin Elmer, Foster City, CA, USA). The level of the CD95L and CD95 mRNA, relative to b-actin mRNA, was calculated using the formula:
Relative mRNA expression =2 7(Ct of CD95L or CD95 7Ct of b-actin) , where Ct is the threshold cycle value. Figure 8 Parthenolide inhibited CD95L and CD95 expression and down-regulates AICD in reactivated day 6 T cells. (A) Fresh isolated human peripheral blood T cells were preactivated for 6 days as previously described. 14 The day 6 T cells were restimulated by aCD3 in the absence or presence of 2.5 mM parthenolide (added 1 h before activation) for different times as indicated. The cells were harvested and analyzed for cell-surface expression levels of CD95L protein. 
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